Gregory C. Connolly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gregory C. Connolly has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Alok A. Khorana
Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3 shared publications J. Lin
3 shared publicationsA. A. Khorana
2 shared publicationsCharles W. Francis
James P. Wilmot Cancer Center, Department of Medicine, and Division of Hematology/Oncology, University of Rochester, Rochester, NY
2 shared publicationsM. R. Dalal
2 shared publicationsSaman Safadjou
2 shared publications
Latest Publications
- 1 June 2014
- Published by Elsevier in Seminars in Oncology
- Vol. 41 (3) , 302-310
Platelets and Cancer-Associated Thrombosis
- 1 June 2014
- Published by Elsevier in Seminars in Oncology
- Vol. 41 (3) , 302-310
Platelets and Cancer-Associated Thrombosis
- 1 November 2013
- Published by Elsevier in Clinical Lung Cancer
- Vol. 14 (6) , 713-718
Prevalence and Clinical Significance of Incidental and Clinically Suspected Venous Thromboembolism in Lung Cancer Patients
- 1 November 2013
- Published by Elsevier in Clinical Lung Cancer
- Vol. 14 (6) , 713-718
Prevalence and Clinical Significance of Incidental and Clinically Suspected Venous Thromboembolism in Lung Cancer Patients
- Open Access
- 14 January 2013
- Published by Springer Nature in BMC Gastroenterology
- Vol. 13 (1) , 9
Diabetes mellitus impacts risk of macrovascular invasion in patients undergoing transplantation for hepatocellular carcinoma
Diabetes mellitus (DM) is identified as a negative prognostic indicator in hepatocellular carcinoma (HCC), though the basis for this is unknown.
- 14 January 2013
- Published by Springer Nature in BMC Gastroenterology
- Vol. 13 (1) , 9
Open AccessDiabetes mellitus impacts risk of macrovascular invasion in patients undergoing transplantation for hepatocellular carcinoma
Diabetes mellitus (DM) is identified as a negative prognostic indicator in hepatocellular carcinoma (HCC), though the basis for this is unknown.
- 1 December 2012
- Published by Elsevier in Lung Cancer
- Vol. 78 (3) , 253-258
Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer
- 1 December 2012
- Published by Elsevier in Lung Cancer
- Vol. 78 (3) , 253-258
Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer
- 16 October 2012
- Published by Taylor & Francis in Cancer Investigation
- Vol. 30 (10) , 698-702
Diabetes Mellitus Is Associated With the Presence of Metastatic Spread at Disease Presentation in Hepatocellular Carcinoma
Purpose: Diabetes mellitus (DM) is identified as a negative prognostic indicator in hepatocellular carcinoma (HCC). Methods: A retrospective review of HCC patients was conducted to assess the effect of DM on clinical variables. Results: Ninety-seven of 265 (34%) patients had DM at the time of diagnosis. Distant metastasis was found in 33% (30/91) of patients with DM compared with only 9.7% (17/174) of those without DM (OR: 4.5, 95% CI: 2.3–8.8, p < .0001). This difference remained significant when adjusting for other clinical variables (OR: 10.0, 95% CI: 3.9–25.7, p < .0001). Conclusions: DM is associated with the presence of metastatic disease among a single institution cohort of HCC patients.
- 16 October 2012
- Published by Taylor & Francis in Cancer Investigation
- Vol. 30 (10) , 698-702
Diabetes Mellitus Is Associated With the Presence of Metastatic Spread at Disease Presentation in Hepatocellular Carcinoma
Purpose: Diabetes mellitus (DM) is identified as a negative prognostic indicator in hepatocellular carcinoma (HCC). Methods: A retrospective review of HCC patients was conducted to assess the effect of DM on clinical variables. Results: Ninety-seven of 265 (34%) patients had DM at the time of diagnosis. Distant metastasis was found in 33% (30/91) of patients with DM compared with only 9.7% (17/174) of those without DM (OR: 4.5, 95% CI: 2.3–8.8, p < .0001). This difference remained significant when adjusting for other clinical variables (OR: 10.0, 95% CI: 3.9–25.7, p < .0001). Conclusions: DM is associated with the presence of metastatic disease among a single institution cohort of HCC patients.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , e19543
Does bevacizumab increase the risk of venous thromboembolism? A cohort study.
E19543 Background: Bevacizumab has been associated with thrombotic events in cancer patients, but results from recent pooled analyses of clinical trials have produced conflicting data. Methods: Data were extracted from the IMS Patient-Centric Database of commercially insured patients in the United States. Demographics/clinical characteristics of ambulatory adult patients with cancer who were initiating chemotherapy (n=17,284) and a matched control cohort without cancer (n=17,284) were evaluated. Incidence of venous thromboembolism (VTE), bleeding, resource utilization, and cost were recorded during a follow-up period of 3-12 months after initiation of chemotherapy in the cancer cohort. Data from the entire cancer cohort and sub-cohort with colorectal cancer only were analyzed. Results: Overall, 2,170 (12.6%) patients experienced VTE in the cancer cohort compared with 237 (1.4%) in the control cohort (P<0.0001). The incidence of VTE events among cancer patients included 7.7% (n=1,336) deep vein thrombosis, 2.4% (n=406) pulmonary embolism, and 2.5% (n=428) both. The respective bleeding rates were 22.4% (n=3,873) and 7.0% (n=1,211; P<0.0001). Among patients with cancer, 11.8% (n=2,035) received bevacizumab. Patients treated with bevacizumab had a significantly increased risk of any VTE event (odds ratio [OR], 1.43; 95% confidence interval [CI], 1.24, 1.65; P<0.0001) and bleeding (OR, 1.39; 95% CI, 1.23, 1.57; P<0.0001) compared with patients not treated with bevacizumab. Of 4,548 patients with colorectal cancer, 480 (10.6%) experienced VTE; 1,135 (25.0%) received bevacizumab. Colorectal cancer patients treated with bevacizumab had a significantly increased risk of VTE (OR, 1.66; 95% CI, 1.32, 2.10; P<0.0001) and bleeding (OR, 1.51; 95% CI, 1.24, 1.83; P<0.0001) compared with those not treated with bevacizumab. Conclusions: The risk of VTE was high among this cohort of ambulatory patients with cancer and sub-cohort of patients with colorectal cancer. The incidence of VTE and bleeding was increased further in those who were treated with bevacizumab. Study funding and editorial support provided by sanofi-aventis U.S.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , e19543
Does bevacizumab increase the risk of venous thromboembolism? A cohort study.
E19543 Background: Bevacizumab has been associated with thrombotic events in cancer patients, but results from recent pooled analyses of clinical trials have produced conflicting data. Methods: Data were extracted from the IMS Patient-Centric Database of commercially insured patients in the United States. Demographics/clinical characteristics of ambulatory adult patients with cancer who were initiating chemotherapy (n=17,284) and a matched control cohort without cancer (n=17,284) were evaluated. Incidence of venous thromboembolism (VTE), bleeding, resource utilization, and cost were recorded during a follow-up period of 3-12 months after initiation of chemotherapy in the cancer cohort. Data from the entire cancer cohort and sub-cohort with colorectal cancer only were analyzed. Results: Overall, 2,170 (12.6%) patients experienced VTE in the cancer cohort compared with 237 (1.4%) in the control cohort (P<0.0001). The incidence of VTE events among cancer patients included 7.7% (n=1,336) deep vein thrombosis, 2.4% (n=406) pulmonary embolism, and 2.5% (n=428) both. The respective bleeding rates were 22.4% (n=3,873) and 7.0% (n=1,211; P<0.0001). Among patients with cancer, 11.8% (n=2,035) received bevacizumab. Patients treated with bevacizumab had a significantly increased risk of any VTE event (odds ratio [OR], 1.43; 95% confidence interval [CI], 1.24, 1.65; P<0.0001) and bleeding (OR, 1.39; 95% CI, 1.23, 1.57; P<0.0001) compared with patients not treated with bevacizumab. Of 4,548 patients with colorectal cancer, 480 (10.6%) experienced VTE; 1,135 (25.0%) received bevacizumab. Colorectal cancer patients treated with bevacizumab had a significantly increased risk of VTE (OR, 1.66; 95% CI, 1.32, 2.10; P<0.0001) and bleeding (OR, 1.51; 95% CI, 1.24, 1.83; P<0.0001) compared with those not treated with bevacizumab. Conclusions: The risk of VTE was high among this cohort of ambulatory patients with cancer and sub-cohort of patients with colorectal cancer. The incidence of VTE and bleeding was increased further in those who were treated with bevacizumab. Study funding and editorial support provided by sanofi-aventis U.S.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , 7066
Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer.
7066 Background: The incidence of VTE among lung cancer patients reported in hospital-discharge database studies and single-institution studies is 2%-13%. The incidence and economic impact of lung cancer–associated VTE is unknown in the ambulatory setting, where most cancer care occurs. This retrospective cohort analysis examined incidence and risk factors for VTE in ambulatory patients with primary lung tumors who were starting chemotherapy. Methods: Data were extracted from the IMS Patient-Centric database, a large administrative database of US healthcare claims. Demographics/clinical characteristics and healthcare resource utilization of patients with solid tumors, including lung, and patients in a matched control cohort without cancer were evaluated. The incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and DVT+PE was recorded during 3- to 12-month follow-up after chemotherapy initiation in the lung cancer cohort. Results: Lung cancer (n=6,732) and control (n=17,284) cohorts had 51% women, with a mean age of 64 years. Respective mean Charlson Comorbidity Index (CCI) scores were 6.7 and 0.6. VTE occurred in 13.9% of the lung cancer cohort (odds ratio [OR], 3.15; 95% confidence interval [CI], 2.55, 3.89) and 1.4% of the control cohort (P<0.0001). The incidence of DVT, PE, and DVT+PE was 7.4%, 3.6%, and 2.9%, respectively, in the lung cancer cohort vs 1.0%, 0.2%, and 0.2% in the control cohort (P<0.0001 for all comparisons). The use of erythropoiesis-stimulating agents (ESAs; OR, 1.63; 95% CI, 1.40, 1.89; P<0.0001 vs no ESA), CCI ≥5 (OR, 2.56; 95% CI, 1.02, 6.39; P=0.045 vs CCI <5), and congestive heart failure (CHF; OR, 1.29; 95% CI, 1.01, 1.66; P=0.045 vs no CHF) were associated with VTE. Bleeding occurred in 22.1% of the lung cancer cohort and 7.0% of the control cohort (P<0.0001). Among lung cancer patients, VTE was associated with a 39.5% higher total medical cost than non-VTE (P<0.0001). Conclusions: VTE is highly prevalent among patients with lung cancer receiving chemotherapy and is associated with a significant increase in healthcare resource utilization. Disclosure: Study funding and editorial support provided by sanofi-aventis U.S.
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15_suppl) , 7066
Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer.
7066 Background: The incidence of VTE among lung cancer patients reported in hospital-discharge database studies and single-institution studies is 2%-13%. The incidence and economic impact of lung cancer–associated VTE is unknown in the ambulatory setting, where most cancer care occurs. This retrospective cohort analysis examined incidence and risk factors for VTE in ambulatory patients with primary lung tumors who were starting chemotherapy. Methods: Data were extracted from the IMS Patient-Centric database, a large administrative database of US healthcare claims. Demographics/clinical characteristics and healthcare resource utilization of patients with solid tumors, including lung, and patients in a matched control cohort without cancer were evaluated. The incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and DVT+PE was recorded during 3- to 12-month follow-up after chemotherapy initiation in the lung cancer cohort. Results: Lung cancer (n=6,732) and control (n=17,284) cohorts had 51% women, with a mean age of 64 years. Respective mean Charlson Comorbidity Index (CCI) scores were 6.7 and 0.6. VTE occurred in 13.9% of the lung cancer cohort (odds ratio [OR], 3.15; 95% confidence interval [CI], 2.55, 3.89) and 1.4% of the control cohort (P<0.0001). The incidence of DVT, PE, and DVT+PE was 7.4%, 3.6%, and 2.9%, respectively, in the lung cancer cohort vs 1.0%, 0.2%, and 0.2% in the control cohort (P<0.0001 for all comparisons). The use of erythropoiesis-stimulating agents (ESAs; OR, 1.63; 95% CI, 1.40, 1.89; P<0.0001 vs no ESA), CCI ≥5 (OR, 2.56; 95% CI, 1.02, 6.39; P=0.045 vs CCI <5), and congestive heart failure (CHF; OR, 1.29; 95% CI, 1.01, 1.66; P=0.045 vs no CHF) were associated with VTE. Bleeding occurred in 22.1% of the lung cancer cohort and 7.0% of the control cohort (P<0.0001). Among lung cancer patients, VTE was associated with a 39.5% higher total medical cost than non-VTE (P<0.0001). Conclusions: VTE is highly prevalent among patients with lung cancer receiving chemotherapy and is associated with a significant increase in healthcare resource utilization. Disclosure: Study funding and editorial support provided by sanofi-aventis U.S.